A new sustained-release tablet formulation of procainamide. 1973

D Fremstad, and S Dahl, and S Jacobsen, and P K Lunde, and K J Nådland, and A A Marthinsen, and T Waaler, and K H Landmark

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011342 Procainamide A class Ia antiarrhythmic drug that is structurally-related to PROCAINE. Procaine Amide,Apo-Procainamide,Biocoryl,Novocainamide,Novocamid,Procainamide Hydrochloride,Procamide,Procan,Procan SR,Procanbid,Pronestyl,Rhythmin,Amide, Procaine,Hydrochloride, Procainamide
D002021 Buffers A chemical system that functions to control the levels of specific ions in solution. When the level of hydrogen ion in solution is controlled the system is called a pH buffer. Buffer
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D001145 Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction. Arrhythmia,Arrythmia,Cardiac Arrhythmia,Cardiac Arrhythmias,Cardiac Dysrhythmia,Arrhythmia, Cardiac,Dysrhythmia, Cardiac
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities

Related Publications

D Fremstad, and S Dahl, and S Jacobsen, and P K Lunde, and K J Nådland, and A A Marthinsen, and T Waaler, and K H Landmark
November 1983, American heart journal,
D Fremstad, and S Dahl, and S Jacobsen, and P K Lunde, and K J Nådland, and A A Marthinsen, and T Waaler, and K H Landmark
February 2001, Drug development and industrial pharmacy,
D Fremstad, and S Dahl, and S Jacobsen, and P K Lunde, and K J Nådland, and A A Marthinsen, and T Waaler, and K H Landmark
November 1988, Yao xue xue bao = Acta pharmaceutica Sinica,
D Fremstad, and S Dahl, and S Jacobsen, and P K Lunde, and K J Nådland, and A A Marthinsen, and T Waaler, and K H Landmark
June 1983, American heart journal,
D Fremstad, and S Dahl, and S Jacobsen, and P K Lunde, and K J Nådland, and A A Marthinsen, and T Waaler, and K H Landmark
January 2002, Drug delivery,
D Fremstad, and S Dahl, and S Jacobsen, and P K Lunde, and K J Nådland, and A A Marthinsen, and T Waaler, and K H Landmark
January 2016, Drug development and industrial pharmacy,
D Fremstad, and S Dahl, and S Jacobsen, and P K Lunde, and K J Nådland, and A A Marthinsen, and T Waaler, and K H Landmark
January 1984, British journal of clinical practice. Supplement,
D Fremstad, and S Dahl, and S Jacobsen, and P K Lunde, and K J Nådland, and A A Marthinsen, and T Waaler, and K H Landmark
June 1984, Drug intelligence & clinical pharmacy,
D Fremstad, and S Dahl, and S Jacobsen, and P K Lunde, and K J Nådland, and A A Marthinsen, and T Waaler, and K H Landmark
October 1987, International journal of clinical pharmacology, therapy, and toxicology,
D Fremstad, and S Dahl, and S Jacobsen, and P K Lunde, and K J Nådland, and A A Marthinsen, and T Waaler, and K H Landmark
November 1987, Arerugi = [Allergy],
Copied contents to your clipboard!